RxDoctor Payments Data

Colin Wright, MD

Cardiovascular Disease · Utica, NYNPI 1790105641

Payments from drug & device makers

$8,393in general payments, 2019–2025

Across 202 payments — averaging $41.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$6K
  • Abbott$565
  • Abiomed$464
  • Novartis$285
  • Medtronic$267
  • Pfizer$199
  • plus $511 from 12 others

What the payments were for

  • Travel & lodging$1,64920%
  • Food & beverage$6,74480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,393 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$430,371
Medicare patients
1,263
Services billed
3,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$314,353
EntrestoSacubitril/Valsartan159$188,267
XareltoRivaroxaban85$92,086
JardianceEmpagliflozin64$76,362
BrilintaTicagrelor29$26,072
Repatha SureclickEvolocumab11$14,650
Metoprolol Succinate528$9,164
Rosuvastatin Calcium313$5,349
Ranolazine ErRanolazine53$5,300
Bisoprolol Fumarate133$4,541
Atorvastatin Calcium275$3,616
Torsemide134$3,116
Valsartan107$2,536
Amlodipine Besylate312$2,218
ClopidogrelClopidogrel Bisulfate165$2,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$314,353253 claims
NovartisEntresto$285$188,267159 claims
Johnson & JohnsonXarelto$13$92,08685 claims
Boehringer IngelheimJardiance$33$76,36264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →